• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 3. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 4. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 5. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

Recent Advances in the Study of 4-(Cyclopropylmethyl)piperidine-4-carbonitrile (CAS: 882035-12-3)

4-(Cyclopropylmethyl)piperidine-4-carbonitrile (CAS: 882035-12-3) is a chemical compound of significant interest in the field of medicinal chemistry and drug discovery. Recent studies have highlighted its potential as a key intermediate or active pharmaceutical ingredient (API) in the development of novel therapeutics. This research briefing aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, pharmacological properties, and potential applications in treating various diseases.

One of the most notable advancements in the study of 4-(cyclopropylmethyl)piperidine-4-carbonitrile is its role in the synthesis of selective serotonin reuptake inhibitors (SSRIs) and other central nervous system (CNS) targeting drugs. Researchers have demonstrated that this compound can serve as a versatile building block for the development of molecules with improved blood-brain barrier permeability and enhanced receptor binding affinity. A recent study published in the Journal of Medicinal Chemistry detailed a novel synthetic route for this compound, optimizing yield and purity while reducing the environmental impact of the production process.

In addition to its applications in CNS drug development, 4-(cyclopropylmethyl)piperidine-4-carbonitrile has shown promise in oncology research. Preliminary in vitro studies have indicated that derivatives of this compound exhibit potent inhibitory effects on specific kinase enzymes involved in cancer cell proliferation. These findings suggest potential applications in targeted cancer therapies, particularly for tumors with known kinase mutations. However, further in vivo studies are required to validate these effects and assess the compound's safety profile.

The pharmacological characterization of 4-(cyclopropylmethyl)piperidine-4-carbonitrile has also revealed interesting metabolic properties. Recent pharmacokinetic studies have demonstrated favorable absorption and distribution characteristics, with particular attention to its stability in various physiological conditions. These properties make it an attractive candidate for further drug development, though researchers note the need for additional studies to fully understand its metabolism and potential drug-drug interactions.

From a structural perspective, computational chemistry approaches have been employed to analyze the molecular interactions of 4-(cyclopropylmethyl)piperidine-4-carbonitrile with various biological targets. Molecular docking simulations have provided insights into the compound's binding modes, which could inform the design of more potent and selective derivatives. These computational studies complement experimental findings and contribute to a more comprehensive understanding of the compound's structure-activity relationships.

Looking forward, the research community anticipates several directions for further investigation of 4-(cyclopropylmethyl)piperidine-4-carbonitrile. These include expanded toxicology studies, formulation development for improved bioavailability, and exploration of its potential in combination therapies. As the compound continues to show promise across multiple therapeutic areas, it represents an important focus for ongoing research in chemical biology and pharmaceutical development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)